These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10637718)

  • 41. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.
    Climo MW; Ehlert K; Archer GL
    Antimicrob Agents Chemother; 2001 May; 45(5):1431-7. PubMed ID: 11302806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method.
    Coutant C; Olden D; Bell J; Turnidge JD
    Diagn Microbiol Infect Dis; 1996 May; 25(1):9-13. PubMed ID: 8831039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid.
    Osterlund A; Eden T; Olsson-Liljequist B; Haeggman S; Kahlmeter G;
    Scand J Infect Dis; 2002; 34(10):729-34. PubMed ID: 12477322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.
    Rello J; Sole-Violan J; Sa-Borges M; Garnacho-Montero J; Muñoz E; Sirgo G; Olona M; Diaz E
    Crit Care Med; 2005 Sep; 33(9):1983-7. PubMed ID: 16148469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption.
    Faber M; Rosdahl VT
    J Antimicrob Chemother; 1990 Feb; 25 Suppl B():7-14. PubMed ID: 2312446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fusidic acid as a potential antistaphylococcal agent.
    Nicholson J; Chew T; Smith S
    N Z Med J; 1999 Jul; 112(1091):261-2. PubMed ID: 10448991
    [No Abstract]   [Full Text] [Related]  

  • 47. Staphylococcal bacteraemia and endocarditis and fusidic acid.
    Eykyn SJ
    J Antimicrob Chemother; 1990 Feb; 25 Suppl B():33-8. PubMed ID: 2312444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of withdrawing topical fusidic acid on Staphylococcus aureus resistance rates.
    Wylie G; Dancer SJ; Bilsland D
    Scott Med J; 2011 Feb; 56(1):10-1. PubMed ID: 21515524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.
    Okusanya OO; Tsuji BT; Bülitta JB; Forrest A; Bulik CC; Bhavnani SM; Fernandes P; Ambrose PG
    Diagn Microbiol Infect Dis; 2011 May; 70(1):101-11. PubMed ID: 21513848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.
    Sahm DF; Deane J; Pillar CM; Fernandes P
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4535-6. PubMed ID: 23774441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid detection of oxacillin-resistant Staphylococcus aureus in blood cultures by an impedance method.
    Wu JJ; Huang AH; Dai JH; Chang TC
    J Clin Microbiol; 1997 Jun; 35(6):1460-4. PubMed ID: 9163462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.
    Van der Auwera P; Godard C; Denis C; De Maeyer S; Vanhoof R
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2260-2. PubMed ID: 2073119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bacterial colonization of chronic wounds. Studies on outpatients in a university dermatology clinic with special consideration of ORSA].
    Dissemond J; Schmid EN; Esser S; Witthoff M; Goos M
    Hautarzt; 2004 Mar; 55(3):280-8. PubMed ID: 15029435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus.
    Besier S; Ludwig A; Brade V; Wichelhaus TA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1426-31. PubMed ID: 15793122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.
    Price CTD; Gustafson JE
    J Med Microbiol; 2001 Jan; 50(1):104-106. PubMed ID: 11192496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular analysis of fusidic acid resistance in Staphylococcus aureus.
    Besier S; Ludwig A; Brade V; Wichelhaus TA
    Mol Microbiol; 2003 Jan; 47(2):463-9. PubMed ID: 12519196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of acquired oxacillin resistance in the management and control of Staphylococcus aureus infections.
    Massanari RM; Pfaller MA; Wakefield DS; Hammons GT; McNutt LA; Woolson RF; Helms CM
    J Infect Dis; 1988 Oct; 158(4):702-9. PubMed ID: 3049836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Staphylococcal infections among newborn babies in two towns in north Norway.
    Skjerven O; Melby K; Dramsdahl H; Alvestad PM
    NIPH Ann; 1982 Dec; 5(2):51-6. PubMed ID: 6926464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sensitivity of Staphylococci and enterococci to staphylomycin with special consideration of urine-bacteria].
    Knoll KH
    Arzneimittelforschung; 1969 Jun; 19(6):1021-4. PubMed ID: 4979617
    [No Abstract]   [Full Text] [Related]  

  • 60. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
    Norén T; Akerlund T; Wullt M; Burman LG; Unemo M
    Antimicrob Agents Chemother; 2007 May; 51(5):1840-3. PubMed ID: 17307985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.